OMX-0407 is a novel therapeutic candidate being developed by iOmx Therapeutics AG for the treatment of previously treated solid tumors that cannot be surgically removed. Currently in Phase 1 and Phase 2 trials, it shows promise in addressing unmet medical needs in oncology.